Advertisement
Advertisement
U.S. Markets open in 1 hr 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

Cantabio Pharmaceuticals, Inc. (CTBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.01000.0000 (0.00%)
At close: 02:08PM EDT
Advertisement

Cantabio Pharmaceuticals, Inc.

2225 East Bayshore Road
Suite 200
Palo Alto, CA 94303
United States
844-200-2826
https://www.cantabio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Gergely TothFounder, CEO, Pres & Director157kN/A1974
Dr. Thomas Roger Sawyer M.B.A., Ph.D.CFO & Director109kN/A1970
Dr. Balász HerberthHead of Cell Biology & In Vitro PharmacologyN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Corporate Governance

Cantabio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement